Parvovirus B19 infection in a human immunodeficiency virus-infected patient with anemia

Sheung M. Lau, Wen Liang Yu, Kuan Chih Chow, Jen Hsien Wang

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Anemia is generally attributed to zidovudine therapy in human immunodeficiency virus (HIV)-infected patients, although parvovirus B19 infection has been reported as a rare cause. We report on a 24-year-old homosexual man infected with HIV who presented with anemia. He had received aggressive daily antiretroviral therapy (zidovudine 600 mg, lamivudine 300 mg, and saquinavir 1,800 mg) for 2 years. At the time of admission, his CD4+ count was 10 x 106 cells/L. A bone marrow aspirate smear showed a marked decrease in erythropoiesis and immunocytochemical staining for parvovirus B19 was positive. Parvovirus B19 viral DNA was detected in the peripheral blood using a polymerase chain reaction-based assay. Serologic studies were positive for parvovirus B19 immunoglobulin (Ig)M antibodies, but negative for IgG antibodies. The patient was treated with packed red blood cell transfusion. Zidovudine was stopped and replaced with zalcitibine 2.25 mg daily after anemia occurred. He did not receive intravenous Ig therapy because of its cost. After discontinuation of zidovudine for 1 year, anemia persisted and the patient depended on regular blood transfusions to control the anemia. This case emphasizes that, in addition to drug-related causes, parvovirus B19 infection should be included in the differential diagnosis of chronic anemia in HIV-infected individuals.

Original languageEnglish
Pages (from-to)162-165
Number of pages4
JournalJournal of the Formosan Medical Association = Taiwan yi zhi
Volume99
Issue number2
Publication statusPublished - Feb 2000
Externally publishedYes

Fingerprint

Parvoviridae Infections
Anemia
Zidovudine
HIV
Parvovirus
Saquinavir
Erythrocyte Transfusion
Passive Immunization
Lamivudine
Antibodies
Erythropoiesis
Intravenous Immunoglobulins
Viral DNA
CD4 Lymphocyte Count
Blood Transfusion
Immunoglobulin M
Differential Diagnosis
Immunoglobulin G
Bone Marrow
Staining and Labeling

Keywords

  • Anemia
  • Human immunodeficiency virus
  • Parvovirus B19
  • Zidovudine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Parvovirus B19 infection in a human immunodeficiency virus-infected patient with anemia. / Lau, Sheung M.; Yu, Wen Liang; Chow, Kuan Chih; Wang, Jen Hsien.

In: Journal of the Formosan Medical Association = Taiwan yi zhi, Vol. 99, No. 2, 02.2000, p. 162-165.

Research output: Contribution to journalArticle

@article{25343971f4c34ddf802e83a2f7def381,
title = "Parvovirus B19 infection in a human immunodeficiency virus-infected patient with anemia",
abstract = "Anemia is generally attributed to zidovudine therapy in human immunodeficiency virus (HIV)-infected patients, although parvovirus B19 infection has been reported as a rare cause. We report on a 24-year-old homosexual man infected with HIV who presented with anemia. He had received aggressive daily antiretroviral therapy (zidovudine 600 mg, lamivudine 300 mg, and saquinavir 1,800 mg) for 2 years. At the time of admission, his CD4+ count was 10 x 106 cells/L. A bone marrow aspirate smear showed a marked decrease in erythropoiesis and immunocytochemical staining for parvovirus B19 was positive. Parvovirus B19 viral DNA was detected in the peripheral blood using a polymerase chain reaction-based assay. Serologic studies were positive for parvovirus B19 immunoglobulin (Ig)M antibodies, but negative for IgG antibodies. The patient was treated with packed red blood cell transfusion. Zidovudine was stopped and replaced with zalcitibine 2.25 mg daily after anemia occurred. He did not receive intravenous Ig therapy because of its cost. After discontinuation of zidovudine for 1 year, anemia persisted and the patient depended on regular blood transfusions to control the anemia. This case emphasizes that, in addition to drug-related causes, parvovirus B19 infection should be included in the differential diagnosis of chronic anemia in HIV-infected individuals.",
keywords = "Anemia, Human immunodeficiency virus, Parvovirus B19, Zidovudine",
author = "Lau, {Sheung M.} and Yu, {Wen Liang} and Chow, {Kuan Chih} and Wang, {Jen Hsien}",
year = "2000",
month = "2",
language = "English",
volume = "99",
pages = "162--165",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Elsevier Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Parvovirus B19 infection in a human immunodeficiency virus-infected patient with anemia

AU - Lau, Sheung M.

AU - Yu, Wen Liang

AU - Chow, Kuan Chih

AU - Wang, Jen Hsien

PY - 2000/2

Y1 - 2000/2

N2 - Anemia is generally attributed to zidovudine therapy in human immunodeficiency virus (HIV)-infected patients, although parvovirus B19 infection has been reported as a rare cause. We report on a 24-year-old homosexual man infected with HIV who presented with anemia. He had received aggressive daily antiretroviral therapy (zidovudine 600 mg, lamivudine 300 mg, and saquinavir 1,800 mg) for 2 years. At the time of admission, his CD4+ count was 10 x 106 cells/L. A bone marrow aspirate smear showed a marked decrease in erythropoiesis and immunocytochemical staining for parvovirus B19 was positive. Parvovirus B19 viral DNA was detected in the peripheral blood using a polymerase chain reaction-based assay. Serologic studies were positive for parvovirus B19 immunoglobulin (Ig)M antibodies, but negative for IgG antibodies. The patient was treated with packed red blood cell transfusion. Zidovudine was stopped and replaced with zalcitibine 2.25 mg daily after anemia occurred. He did not receive intravenous Ig therapy because of its cost. After discontinuation of zidovudine for 1 year, anemia persisted and the patient depended on regular blood transfusions to control the anemia. This case emphasizes that, in addition to drug-related causes, parvovirus B19 infection should be included in the differential diagnosis of chronic anemia in HIV-infected individuals.

AB - Anemia is generally attributed to zidovudine therapy in human immunodeficiency virus (HIV)-infected patients, although parvovirus B19 infection has been reported as a rare cause. We report on a 24-year-old homosexual man infected with HIV who presented with anemia. He had received aggressive daily antiretroviral therapy (zidovudine 600 mg, lamivudine 300 mg, and saquinavir 1,800 mg) for 2 years. At the time of admission, his CD4+ count was 10 x 106 cells/L. A bone marrow aspirate smear showed a marked decrease in erythropoiesis and immunocytochemical staining for parvovirus B19 was positive. Parvovirus B19 viral DNA was detected in the peripheral blood using a polymerase chain reaction-based assay. Serologic studies were positive for parvovirus B19 immunoglobulin (Ig)M antibodies, but negative for IgG antibodies. The patient was treated with packed red blood cell transfusion. Zidovudine was stopped and replaced with zalcitibine 2.25 mg daily after anemia occurred. He did not receive intravenous Ig therapy because of its cost. After discontinuation of zidovudine for 1 year, anemia persisted and the patient depended on regular blood transfusions to control the anemia. This case emphasizes that, in addition to drug-related causes, parvovirus B19 infection should be included in the differential diagnosis of chronic anemia in HIV-infected individuals.

KW - Anemia

KW - Human immunodeficiency virus

KW - Parvovirus B19

KW - Zidovudine

UR - http://www.scopus.com/inward/record.url?scp=0034112369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034112369&partnerID=8YFLogxK

M3 - Article

C2 - 10770032

AN - SCOPUS:0034112369

VL - 99

SP - 162

EP - 165

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

SN - 0929-6646

IS - 2

ER -